Unibest 优贝德
← Back to patent-cliff list

磷酸芦可替尼

Tier A — Act now

Ruxolitinib Phosphate · all drugs expiring in 2028 →

Incyte Corp
Originator
2011
First approval
2028
Expiry (public)
$5.88B ▲
Peak sales
化学药
Type

Targets：JAK2、JAK1

Brand：百卢妥、OPZELURA、Jakafi、Jakavi

Indications (approved)：特应性皮炎、白癜风、移植物抗宿主病、骨髓纤维化、真性红细胞增多症

Regional status

US
批准上市
2011-11-16
EU
批准上市
2012-08-23
China
批准上市
2017-03-10
Japan
批准上市
2014-07-04

Synthetic routes & intermediates4 routes

Originator routes × 1Optimised (non-patent) × 3Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 5 · Total yield 171.7 mg
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
RUXO-0013680-69-1Available4-chloro-7H-pyrrolo[2,3-d]pyrimidine
RUXO-002941685-26-3Available4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
RUXO-003269410-08-4Available4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
RUXO-004941685-27-4Available4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
RUXO-005591769-05-0Available3-cyclopentylacrylonitrile
RUXO-006941685-40-1Available(R)-3-cyclopentyl-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile
OptimisedRoute 2Steps 9 · Total yield 634.2 g
Synthetic routes & intermediates Route 2
CodeCAS No.Intermediate
RUXO-0013680-69-1Available4-chloro-7H-pyrrolo[2,3-d]pyrimidine
RUXO-0071146629-75-5Available(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-0081029716-44-6Available1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
RUXO-0091146629-76-6Available(4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-0101146629-77-7Available(4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-011941685-68-3Available3-cyclopentylpropiolonitrile
RUXO-0121236033-17-2Available(Z)-(4-(1-(2-cyano-1-cyclopentylvinyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-0131236033-18-3Available(Z)-(4-(1-(3-amino-1-cyclopentyl-3-oxoprop-1-en-1-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-0141236032-96-4Available(R)-(4-(1-(3-amino-1-cyclopentyl-3-oxopropyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-0151146629-80-2Available(R)-(4-(1-(2-cyano-1-cyclopentylethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
OptimisedRoute 3Steps 4 · Total yield /
Synthetic routes & intermediates Route 3
CodeCAS No.Intermediate
RUXO-0101146629-77-7Available(4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-0151146629-80-2Available(R)-(4-(1-(2-cyano-1-cyclopentylethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
RUXO-016872-53-7Availablecyclopentanecarbaldehyde
RUXO-0172136-75-6Available2-(triphenylphosphoranylidene)acetaldehyde
RUXO-018118235-51-1Available(E)-3-cyclopentylacrylaldehyde
RUXO-0191146629-79-9Available(R)-(4-(1-(1-cyclopentyl-3-oxopropyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
OptimisedRoute 4Steps 4 · Total yield 204.3 mg
Synthetic routes & intermediates Route 4
CodeCAS No.Intermediate
RUXO-0013680-69-1Available4-chloro-7H-pyrrolo[2,3-d]pyrimidine
RUXO-018118235-51-1Available(E)-3-cyclopentylacrylaldehyde
RUXO-0202075-45-8Available4-bromo-1H-pyrazole
RUXO-0211146629-82-4Available(R)-3-(4-bromo-1H-pyrazol-1-yl)-3-cyclopentylpropanal
RUXO-0221146629-83-5Available(R)-3-(4-bromo-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
RUXO-02373183-34-3Available4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
RUXO-0241146629-84-6Available(R)-3-cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

Frequently asked questions

What are the approved indications of Ruxolitinib Phosphate?

Approved indications include: 特应性皮炎, 白癜风, 移植物抗宿主病, 骨髓纤维化, 真性红细胞增多症.

When does the Ruxolitinib Phosphate patent expire?

Based on public sources, the Ruxolitinib Phosphate patent expires in 2028.

How many synthesis routes are recorded for Ruxolitinib Phosphate?

4 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Ruxolitinib Phosphate intermediates?

24 intermediate CAS of Ruxolitinib Phosphate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Ruxolitinib Phosphate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24